PharmaCom BioVet, Inc. Provides Update On Corporate Development

  PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to provide shareholders with a corporate update on the company's development within the field of specialized veterinary oncology. As previously announced, the company is undergoing a strategic plan establishing Veterinary Oncology Treatment Centers on a nationwide basis with a view to towards becoming the premier cancer treatment provider for animals. Under this initiative, PharmaCom BioVet, Inc. is pleased to announce that significant development progress has been made to establishing the first center. Management has recently been focusing on the logistics of starting the first center with respect to analysis of facilities, equipment, staffing and strategic partnerships. It is envisioned initial care center will be launched within a major veterinary research and care facility in a Missouri community. Further information of the location and opening date will be released by the company in due course.

About Us:

PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PharmaCom BioVet Inc.'s management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. The company has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a greater life expectancy and decreased suffering.

On behalf of the Board of Directors,

Mr. Gary Berthold

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contacts: PharmaCom BioVet, Inc. Gary Berthold [phone]